Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (22075)	3/10/2000 12:08:00 PM
From: Sye Walsh	Read Replies (1) \| Respond to of 57584

Interesting article in II (April) on Merck. They question wether they can make it alone without losing earnings growth. 4 of their big drugs loose patent protection by 2002, three of these have earned $1 billion in revenue. There will be further mergers in the industry to compete with the Pharmacia/Upjohn and Monsanto, Glaxo/Smithkline, Pfizer/Warner-Lambert mergers. II's most likely merger candidates: Eli Lilly Schering-Plough Johnson & Johnson Merck